Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients (Q33496780)

27 July 2017

title

Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients (English)

1 reference

27 July 2017

0 references

Coagulation factor VIII

0 references

1

Kathelijn Fischer

0 references

Cecile Denis

object named as

Cécile V Denis

5

0 references

Peter J Lenting

object named as

Peter J Lenting

7

0 references

author name string

Ronan Pendu

2

1 reference

27 July 2017

Carina J van Schooten

3

1 reference

27 July 2017

Karin van Dijk

4

1 reference

27 July 2017

H Marijke van den Berg

6

1 reference

27 July 2017

language of work or name

English

0 references

publication date

25 August 2009

1 reference

27 July 2017

1 reference

27 July 2017

volume

4

1 reference

27 July 2017

issue

8

1 reference

27 July 2017

page(s)

e6745

1 reference

Creative Commons Attribution 4.0 International

27 July 2017

copyright license

start time

25 August 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

Clearance mechanisms of von Willebrand factor and factor VIII.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

Haemophilia A: from mutation analysis to new therapies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

Consensus perspectives on prophylactic therapy for haemophilia: summary statement

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP).

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

The life cycle of coagulation factor VIII in view of its structure and function

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

A mathematical model of coagulation factor VIII kinetics

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

The influence of D.D.A.V.P. on the survival of factor VIII in severe haemophiliacs

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.

14 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0006745

Lifestyle and hemostatic risk factors for ischemic heart disease : the Caerphilly Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0006745

Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0006745

Cysteine-mutations in von Willebrand factor associated with increased clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0006745

Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0006745

Factor VIII half-life and clinical phenotype of severe hemophilia A.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2727052

The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A

31 October 2018

1 reference

12 December 2020

Mapping the collagen-binding site in the von Willebrand factor-A3 domain

1 reference

12 December 2020

High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII

1 reference

12 December 2020

The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis

1 reference

12 December 2020

Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease

1 reference

12 December 2020

von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0006745

Identifiers

DOI

1 reference

27 July 2017

0 references

1 reference

27 July 2017

1 reference